Brand-Generic Pay-For-Delay Deals May Become Extinct, FTC Finds

Only one of 232 brand-generic patent suit settlements in the US during FY 2016 contained a side deal or commitment not to market an authorized generic.  

3D rendering of Tyrannosaurus Rex near extinction. - Illustration
Will pay-for-delay deals between brand and generic companies go the way of T. Rex? • Source: Shutterstock

The US Federal Trade Commission found that only one patent settlement agreement between brand and generic companies in fiscal year 2016 contained a side deal or commitment not to market an authorized generic, suggesting that so-called pay-for-delay deals may become a thing of the past.

In its latest report on brand-generic patent settlements, released on 23 May, the FTC does not use the term...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Generics

More from Biosimilars & Generics